ATI-045-AD-201 Enrolling

Atopic Dermatitis Study (34 Weeks)


Treatment: Injection Age: Between 18 and 70 Years


Who Can Participate?

Adults aged between 18 and 70 with AD may participate.

 

Inclusion Criteria

  • have chronic AD that has been present for ≥ 6 months
  • have ≥ 10% body surface area (BSA) of AD involvement
  • have a history of inadequate response to treatment for AD with topical medications; or determination that topical treatments are otherwise medically inadvisable

 

Participant Information

  • Participate and receive study treatment at no cost
  • Regular visits with study doctors who specialise in treating atopic dermatitis (18 visits)
  • Will receive an investigative subcutaneous treatment (study drug) or a placebo
  • Reimbursement for study-related expenses may be provided

 

How Long Will The Study Last?

34 weeks


Participating Locations

COUNTRY
country-icon
Canada

Participating Experts

No Doctors Found

You May Also Be Interested In

Similar Trials

No Similar Trials Found

The following information is from ClinicalTrials.gov

Last Update Posted: June 24, 2025

Official Title

A Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ATI-045 in Patients With Moderate-to-Severe Atopic Dermatitis

ClinicalTrials.gov ID

NCT07011706

Sponsor

Aclaris Therapeutics, Inc.

Study Description

  • Brief Summary:

    This study evaluates ATI-045 versus placebo in patients with Moderate-to-Severe Atopic Dermatitis.

  • Condition or Disease:

    Atopic Dermatitis,Atopic,Dermatitis,AD,Eczema

  • Intervention/Treatment:

    Drug: ATI-045 Drug: Placebo
  • Phase:

    PHASE2

  • Ages Eligible for Study:

    18 Years and 70 Years (ADULT,OLDER_ADULT)

  • Sexes Eligible for Study:

    ALL

Inclusion Criteria

  • have chronic AD that has been present for ≥ 6 months
  • have ≥ 10% body surface area (BSA) of AD involvement
  • have a history of inadequate response to treatment for AD with topical medications; or determination that topical treatments are otherwise medically inadvisable

Terms and Conditions – ClinicalTrials.gov
Purpose of ClinicalTrials.gov Database. The U.S. National Institutes of Health, Department of Health and Human Services, through its National Library of Medicine, has developed ClinicalTrials.gov to provide patients, family members, and members of the public current information about clinical research studies.



about-icon

Learn More About

ECZEMA - ATOPIC DERMATITIS

Learn More
2025 all rights reserved Probity Medical Research Inc
find a trial
General Registration

Can’t find a trial? Not sure which trial to choose? Complete a general registration and we’ll contact you with suitable trials.

Register
filter trials
Skip to content